Lung CancerPhase 2NCT00057746
Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 2 study testing Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx and Prophylactic cranial irradiation, 1.5 Gy fx in people with Lung Cancer, run by Radiation Therapy Oncology Group at 222 sites in 2 countries.
Trial summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung cancer while taking into account chronic neurotoxicity from radiation therapy. Read more about this study
- Who is it for?
- Ages Up to 120 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx and Prophylactic cranial irradiation, 1.5 Gy fx
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 265 participants
- Where
- 222 sitesin 2 countries
- Study dates
- Feb 2003to Nov 2013
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 120 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed small cell lung cancer by fine needle aspiration, biopsy, or 2 positive sputa
- Limited stage (I-IIIB)
- Confined to 1 hemithorax
- No T4 based on malignant pleural effusion, or N3 disease based on contralateral hilar or contralateral supraclavicular involvement
- Complete response after induction chemotherapy (with or without thoracic radiotherapy)
- Consolidative chest radiotherapy may be initiated before study
- No radiographic evidence of any of the following:
- Brain metastases
- Normal brain CT scan or MRI less than 1 month before study
- Ipsilateral lung metastases
- Malignant pleural effusion
- Minimal pleural effusion by chest CT scan allowed, but not by chest x-ray
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 75,000/mm^3
- Hemoglobin at least 10.0 g/dL^
Hepatic
- Not specified
Renal
- Not specified
Pulmonary
- See Disease Characteristics
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Neurological function class 1 or 2
- No epilepsy requiring permanent oral medication
- No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No other serious medical or psychiatric condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
- At least 1 week since prior chemotherapy
- No concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- No prior external beam radiotherapy to the head or neck, including stereotactic radiotherapy
- Concurrent thoracic radiotherapy allowed
Surgery
- Not specified
Other
- No concurrent antitumor agents
Trial locations and contacts
222 sites in 2 countries.
222 sites in 2 countries
United States217 sites
Rosenfeld Cancer Center at Abington Memorial Hospital
Abington, Pennsylvania, 19001
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
McFarland Clinic, PC
Ames, Iowa, 50010
Saint John's Cancer Center at Saint John's Medical Center
Anderson, Indiana, 46016
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Arlington Cancer Center - Arlington
Arlington, Texas, 76012-2510
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Auburn Radiation Oncology
Auburn, California, 95603
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Joseph Cancer Center
Bellingham, Washington, 98225
St. Luke's Cancer Network at St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Mecosta County Medical Center
Big Rapids, Michigan, 49307
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Birmingham, Alabama, 35294
St. Joseph Medical Center
Bloomington, Illinois, 61701
Boston University Cancer Research Center
Boston, Massachusetts, 02118
Harrison Medical Center
Bremerton, Washington, 98310
Ocean Medical Center at Meridian Health
Brick, New Jersey, 08724
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Radiation Oncology Centers - Cameron Park
Cameron Park, California, 95682
Graham Hospital
Canton, Illinois, 61520
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Cancer Institute of Cape Girardeau, LLC
Cape Girardeau, Missouri, 63703
Memorial Hospital
Carthage, Illinois, 62321
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Huron Hospital Cancer Care Center
Cleveland, Ohio, 44112
Euclid Hospital
Cleveland, Ohio, 44119
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Memorial Hospital Cancer Center - Colorado Springs
Colorado Springs, Colorado, 80909
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Dale and Frances Hughes Cancer Center at Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
John F. Kennedy Medical Center
Edison, New Jersey, 08818
St. Anthony's Memorial Hospital
Effingham, Illinois, 62401
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Union Hospital Cancer Program at Union Hospital
Elkton MD, Maryland, 21921
Eureka Community Hospital
Eureka, Illinois, 61530
Hudner Oncology Center at Saint Anne's Hospital - Fall River
Fall River, Massachusetts, 02721
Parkview Regional Cancer Center at Parkview Health
Fort Wayne, Indiana, 46805
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0232
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Wayne Radiation Oncology
Goldsboro, North Carolina, 27534
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Metro Health Hospital
Grand Rapids, Michigan, 49506
Three Rivers Community Hospital
Grants Pass, Oregon, 97527
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Leo W. Jenkins Cancer Center at ECU Medical School
Greenville, North Carolina, 27835-6028
CCOP - Greenville
Greenville, South Carolina, 29615
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Mason District Hospital
Havana, Illinois, 62644
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Holland Community Hospital
Holland, Michigan, 49423
Hopedale Medical Complex
Hopedale, Illinois, 61747
M. D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030-4009
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202-5289
Veterans Affairs Medical Center - Indianapolis
Indianapolis, Indiana, 46202
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242-1002
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists
Kinston, North Carolina, 28501
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
La Grange Memorial Hospital
La Grange, Illinois, 60525
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, 92093-0658
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
Lucille P. Markey Cancer Center at University of Kentucky
Lexington, Kentucky, 40536-0093
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Monmouth Medical Center
Long Branch, New Jersey, 07740-6395
McDonough District Hospital
Macomb, Illinois, 61455
Immanuel St. Joseph's
Mankato, Minnesota, 56002
MedCentral - Mansfield Hospital
Mansfield, Ohio, 44903
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Marlton, New Jersey, 08053
St. Luke's Hospital
Maumee, Ohio, 43537
Hillcrest Cancer Center at Hillcrest Hospital
Mayfield Heights, Ohio, 44124
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Dubs Cancer Center at Rogue Valley Medical Center
Medford, Oregon, 97504
Providence Cancer Center at PMCC
Medford, Oregon, 97504
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, 33136
Baptist-South Miami Regional Cancer Program
Miami, Florida, 33176
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Tucker Center for Cancer Care at Orange Regional Medical Center
Middletown, New York, 10940-4199
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee
Milwaukee, Wisconsin, 53295
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Cancer Center at Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
Murray, Utah, 84157
Hackley Hospital
Muskegon, Michigan, 49442
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Regional Cancer Center at Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
Ogden, Utah, 84403
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Bay Medical
Panama City, Florida, 32401
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Regional Cancer Center at Singing River Hospital
Pascagoula, Mississippi, 39581
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, 19111-2497
Fox Chase Cancer Center CCOP Research Base
Philadelphia, Pennsylvania, 19140
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141
Arizona Oncology Services Foundation
Phoenix, Arizona, 85013
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
Pomona, California, 91767
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center and Children's Hospital
Portland, Oregon, 97227
Hudson Valley Oncology Associates
Poughkeepsie, New York, 12601
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84604
South Suburban Oncology Center
Quincy, Massachusetts, 02169
All Saints Cancer Center at Wheaton Franciscan Healthcare
Racine, Wisconsin, 53405
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Booker Cancer Center at Riverview Medical Center
Red Bank, New Jersey, 07701
Radiation Oncology Associates - Reno
Reno, Nevada, 89509
Highland Hospital of Rochester
Rochester, New York, 14620
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Radiation Oncology Center - Roseville
Roseville, California, 95661
Radiological Associates of Sacramento Medical Group, Incorporated
Sacramento, California, 95815
Mercy General Hospital
Sacramento, California, 95819
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Lakeland Regional Cancer Care Center - St. Joseph
Saint Joseph, Michigan, 49085
Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford
Salem, Ohio, 44460
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67042
Utah Cancer Specialists at UCS Cancer Center
Salt Lake City, Utah, 84106
LDS Hospital
Salt Lake City, Utah, 84143
Firelands Regional Medical Center
Sandusky, Ohio, 44870
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn
Scottsdale, Arizona, 85251
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
Scottsdale, Arizona, 85260
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98122-4307
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Frederick R. and Betty M. Smith Cancer Treatment Center
Sparta, New Jersey, 07871
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
St. Margaret's Hospital
Spring Valley, Illinois, 61362
Valley Cancer Center
Spring Valley, Illinois, 61362
Highlands Oncology Group - Springdale
Springdale, Arkansas, 72764
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
Dixie Regional Medical Center - East Campus
St. George, Utah, 84770
Iredell Memorial Hospital
Statesville, North Carolina, 28677
Flower Hospital Cancer Center
Sylvania, Ohio, 43560
SUNY Upstate Medical University Hospital
Syracuse, New York, 13210
Madigan Army Medical Center - Tacoma
Tacoma, Washington, 98431
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Toledo Hospital
Toledo, Ohio, 43606
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Medical University of Ohio Cancer Center
Toledo, Ohio, 43614
CCOP - Toledo Community Hospital
Toledo, Ohio, 43617
Toledo Clinic, Incorporated - Main Clinic
Toledo, Ohio, 43623
J. Phillip Citta Regional Cancer Center at Community Medical Center
Toms River, New Jersey, 08755
Cotton-O'Neil Cancer Center
Topeka, Kansas, 66606
St. Francis Comprehensive Cancer Center
Topeka, Kansas, 66606
Munson Medical Center
Traverse City, Michigan, 49684
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Solano Radiation Oncology Center
Vacaville, California, 95687
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare
Vineland, New Jersey, 08360
Cancer Institute of New Jersey at Cooper - Voorhees
Voorhees Township, New Jersey, 08043
South Pointe Hospital Cancer Care Center
Warrensville Heights, Ohio, 44122
Waukesha Memorial Hospital Regional Cancer Center
Waukesha, Wisconsin, 53188
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801-2028
Schiffler Cancer Center at Wheeling Hospital
Wheeling, West Virginia, 26003
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67203
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wesley Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Cancer Treatment Center
Wooster, Ohio, 44691
York Cancer Center at Apple Hill Medical Center
York, Pennsylvania, 17405
Canada5 sites
Hopital Notre-Dame du CHUM
Montreal, Quebec, H2L 4M1
McGill Cancer Centre at McGill University
Montreal, H2W 1S6
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, G1R 2J6
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
About this study
Official title: A Phase II Randomized Trial Of Two Dose Schedules For Delivering Prophylactic Cranial Irradiation For Patients With Limited Disease Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung cancer while taking into account chronic neurotoxicity from radiation therapy.
PURPOSE: This randomized phase II trial compares the incidence of chronic neurotoxicity between three different brain irradiation regimens. The corresponding phase III component addressing the prevention of brain metastases was run by EORTC and reported separately (NCT00005062).
Read the detailed description
OBJECTIVES:
- Compare the incidence of chronic neurotoxicity in patients treated with these regimens.
- Compare quality of life of patients treated with these regimens. (phase III closed to accrual as of 12/31/05)
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (60 and under vs over 60) and time since induction therapy (90 days or less vs 91-180 days vs 181-240 days). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients undergo prophylactic cranial irradiation (PCI) once daily 5 days a week. Treatment continues for 2 weeks in the absence of unacceptable toxicity.
- Arm II: Patients undergo PCI once daily 5 days a week. Treatment continues for 2.6 weeks in the absence of unacceptable toxicity.
- Arm III: Patients undergo PCI twice daily 5 days a week. Treatment continues for 3.4 weeks in the absence of unacceptable toxicity.
Quality of life is assessed at baseline, every 6 months for 1 year, and then annually for 3 years.
Patients are followed every 6 months for 1 year and then annually for 3 years.
PROJECTED ACCRUAL: A total of 264 patients will be accrued for this study within 3.5 years.
- Conditions
- Lung Cancer
- Being tested
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
- Keywords
- limited stage small cell lung cancer
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prophylactic cranial irradiation, 2.5 Gy fxRadiation
Also called PCI
Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
Prophylactic cranial irradiation, 2.0 Gy fxRadiation
Also called PCI
Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
Prophylactic cranial irradiation, 1.5 Gy fxRadiation
Also called PCI
Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Active comparator | Prophylactic cranial irradiation, 2.5 Gy fx Receives: Radiation: Prophylactic cranial irradiation, 2.5 Gy fx |
| Arm II | Experimental | Prophylactic cranial irradiation, 2.0 Gy fx Receives: Radiation: Prophylactic cranial irradiation, 2.0 Gy fx |
| Arm III | Experimental | Prophylactic cranial irradiation, 1.5 Gy fx Receives: Radiation: Prophylactic cranial irradiation, 1.5 Gy fx |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Chronic Neurotoxicity
Chronic neurotoxicity is defined as a drop in one standard error of measurement (SEM) in any one of the three tests comprising the neuropsychological test battery (Hopkins Verbal Learning Test, Controlled Word Association Test, and Trail-Making Test) without development of brain metastasis by one year. The SEM is calculated as the standard deviation of the baseline test multiplied by the square root of one minus the published reliability coefficient for the test.
Measured: From study registration to one year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2003 (estimated)
- Study startFeb 2003
- Primary completionMay 2009
- Study completionNov 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 265 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Aaron H. Wolfson, MD, Study chair, University of Miami Sylvester Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00057746
- Sponsor's protocol ID
- RTOG-0212
- Other IDs
- CDR0000258668
- Status last verified
- Apr 2016
- First submitted
- 7 Apr 2003
- Last updated
- 25 May 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Gondi V, Paulus R, Bruner D, et al.: Prognostic significance of QOL deterioration during early lung cancer survivorship: secondary analysis of RTOG 0212 and 0214. [Abstract] J Clin Oncol 29 (Suppl 15): A-6061, 2011.
Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 May;10(5):467-74. doi: 10.1016/S1470-2045(09)70101-9. Epub 2009 Apr 20.
PubMed 19386548Pechoux CL, Hatton M, Kobierska A, et al.: Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): primary endpoint analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212). [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA7514, 2008.
Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, Werner-Wasik M, Videtic GM, Garces YI, Choy H. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):77-84. doi: 10.1016/j.ijrobp.2010.05.013. Epub 2010 Aug 26.
PubMed 20800380
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Randomized Trial Of Two Dose Schedules For Delivering Prophylactic Cranial Irradiation For Patients With Limited Disease Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT00057746
- Acronym / sponsor ID
- RTOG-0212
- Conditions
- Lung Cancer
- Keywords
- limited stage small cell lung cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 265 participants (actual)
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Feb 2003
- Primary completion
- May 2009 (actual)
- Study completion
- Nov 2013 (actual)
- First posted
- 9 Apr 2003 (estimated)
- Results
- Posted 25 May 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung cancer while taking into account chronic neurotoxicity from radiation therapy.
PURPOSE: This randomized phase II trial compares the incidence of chronic neurotoxicity between three different brain irradiation regimens. The corresponding phase III component addressing the prevention of brain metastases was run by EORTC and reported separately (NCT00005062).
Detailed description
OBJECTIVES:
- Compare the incidence of chronic neurotoxicity in patients treated with these regimens.
- Compare quality of life of patients treated with these regimens. (phase III closed to accrual as of 12/31/05)
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (60 and under vs over 60) and time since induction therapy (90 days or less vs 91-180 days vs 181-240 days). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients undergo prophylactic cranial irradiation (PCI) once daily 5 days a week. Treatment continues for 2 weeks in the absence of unacceptable toxicity.
- Arm II: Patients undergo PCI once daily 5 days a week. Treatment continues for 2.6 weeks in the absence of unacceptable toxicity.
- Arm III: Patients undergo PCI twice daily 5 days a week. Treatment continues for 3.4 weeks in the absence of unacceptable toxicity.
Quality of life is assessed at baseline, every 6 months for 1 year, and then annually for 3 years.
Patients are followed every 6 months for 1 year and then annually for 3 years.
PROJECTED ACCRUAL: A total of 264 patients will be accrued for this study within 3.5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm I | Active comparator | Radiation: Prophylactic cranial irradiation, 2.5 Gy fxProphylactic cranial irradiation, 2.5 Gy fx |
| Arm II | Experimental | Radiation: Prophylactic cranial irradiation, 2.0 Gy fxProphylactic cranial irradiation, 2.0 Gy fx |
| Arm III | Experimental | Radiation: Prophylactic cranial irradiation, 1.5 Gy fxProphylactic cranial irradiation, 1.5 Gy fx |
Who may qualify
- Ages
- Up to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prophylactic cranial irradiation, 2.5 Gy fxAlso: PCIProphylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy | Radiation | Arm I |
| Prophylactic cranial irradiation, 2.0 Gy fxAlso: PCIProphylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy | Radiation | Arm II |
| Prophylactic cranial irradiation, 1.5 Gy fxAlso: PCIProphylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy | Radiation | Arm III |
Primary outcome
Incidence of Chronic Neurotoxicity
Time frame: From study registration to one year.
Chronic neurotoxicity is defined as a drop in one standard error of measurement (SEM) in any one of the three tests comprising the neuropsychological test battery (Hopkins Verbal Learning Test, Controlled Word Association Test, and Trail-Making Test) without development of brain metastasis by one year. The SEM is calculated as the standard deviation of the baseline test multiplied by the square root of one minus the published reliability coefficient for the test.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- BackgroundGondi V, Paulus R, Bruner D, et al.: Prognostic significance of QOL deterioration during early lung cancer survivorship: secondary analysis of RTOG 0212 and 0214. [Abstract] J Clin Oncol 29 (Suppl 15): A-6061, 2011.
- Background: PubMed 19386548Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 May;10(5):467-74. doi: 10.1016/S1470-2045(09)70101-9. Epub 2009 Apr 20.
- BackgroundPechoux CL, Hatton M, Kobierska A, et al.: Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): primary endpoint analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212). [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA7514, 2008.
- Results publication: PubMed 20800380Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, Werner-Wasik M, Videtic GM, Garces YI, Choy H. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):77-84. doi: 10.1016/j.ijrobp.2010.05.013. Epub 2010 Aug 26.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aaron H. Wolfson, MD study chair
University of Miami Sylvester Comprehensive Cancer Center
222 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx and Prophylactic cranial irradiation, 1.5 Gy fx in people with Lung Cancer, run by Radiation Therapy Oncology Group at 222 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 222 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 May 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Chronic Neurotoxicity (time frame: From study registration to one year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00057746, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2016.